Novel agonist for the vitamin D receptor (VDR)

Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools

Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA

Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

Novel telomerase inhibitor

Novel Caspase-1 inhibitor

Novel MC1R agonist

Novel potent covalent BRD4 degrader, degrading BRD4 in a proteasome- and RNF4-dependent manner without inhibiting RNF4 autoubiquitination activity

Novel inhibitor of the efflux function of ABCG2, selectively reversing ABCG2-mediated MDR in cancer cells in vitro and in vivo

Novel inhibitor of BCL6

Highly Selective Oral Checkpoint Kinase 1 (CHK1) Inhibitor

Inactive analogue of pictilisib to be used as the negative control

Novel dual FLT3/Aurora A inhibitor, overcoming D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells

Novel CCR4 antagonist, enhancing DC activation and homing to the regional lymph node and showing potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment

Novel MmpL3 inhibitor

Novel sialyltransferase inhibitor (IC 50 : 2 µM)

Novel covalent selective GRK inhibitor, interacting with a nonconserved cysteine (Cys474)

Novel inhibitor of G Protein-Coupled Receptor Kinase

Potent photoprobe as Rho/MKL1/SRF transcription inhibitor

Novel Inhibitor of TonB Function

Novel coupleable ceritinib analog with a linker, also binding multiple other kinases, including FAK1, RSK1/2, ERK1/2, CAMKK2 and FER

Novel Indigoid Anti-tuberculosis Agent; Antimicrobial

Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF3 zinc finger domains

Novel potent orally bioavailable Syk kinase inhibitor

PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays

PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays

Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF1 zinc finger domains

Novel inhibitor of the E2 ubiquitin-conjugating enzyme Cdc34A

FTY720 derivative

The first Gatekeeper RXR antagonist that does not show allosteric inhibition in permissive RXR heterodimers, binding domain (LBD) at the entrance of the ligand binding pocket (LBP), blocking access to the LBP and thus serving as a gatekeeper